Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

September 9, 2020September 9, 2020

Lenabasum Fails to Show Efficacy in Diffuse Cutaneous SSc, Phase 3 Trial Shows

News

Treatment with lenabasum failed to outperform a placebo when given as an add-on to standard immunosuppressants in adults with diffuse cutaneous scleroderma (dcSSc), top-line data from a Phase 3 ... Read more

August 31, 2020August 31, 2020

Phase 2 Trial of CellCept Plus Esbriet for SSc-ILD Enrolling in US

News

The Scleroderma Lung Study III (SLSIII), a Phase 2 clinical trial of oral CellCept (mycophenolate mofetil) alone or in combination with Esbriet (pirfenidone) in scleroderma-associated interstitial lung disease (ILD) is enrolling patients. The trial ... Read more

August 10, 2020August 10, 2020

FLI1 Gene Variant Linked to Increased Scleroderma Risk, Greater Skin Thickness in Study

News

Long stretches of DNA repeats in the FLI1 gene — which gives instructions for a protein that controls the activity of genes — are linked to an increased risk ... Read more

July 27, 2020July 27, 2020

Cell Therapy FCR001 to Enter Phase 1/2a Trial for Diffuse Cutaneous SSc

News

Talaris Therapeutics plans to initiate a Phase 1/2a trial to test its investigational cell therapy, FCR001, in people with diffuse cutaneous systemic sclerosis (dcSSc), the company has announced. The ... Read more

March 30, 2020March 30, 2020

Canada Clears EHP-101, Possible Cannabidiol-derived Treatment

News

The active ingredient in EHP-101 — known as VCE-004.8, derived from synthetic cannabidiol — is not classified as a controlled substance under Canada’s Controlled Drug and Substance Act (CDSA), the potential ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

March 4, 2020March 4, 2020

CHMP Favors EU Approval of Ofev to Preserve Lung Function in SSc-ILD

News

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Ofev (nintedanib) to preserve lung function in people with systemic sclerosis (SSc)-associated interstitial lung disease (SSc-ILD) in the ... Read more

February 28, 2020February 28, 2020

Inhibiting Key Protein May Ease Lung Scarring in Systemic Scleroderma, Study Suggests

News

Inhibiting a protein known as KLHL42 may ease lung fibrosis (scarring) associated with systemic scleroderma (SSc), according to a recent study. The findings were published in an article, “Kelch-like ... Read more

January 24, 2020January 29, 2020

Tests with Hand Function Tasks Better for Assessing Scleroderma Progression, Treatment Response, Study Finds

News

Women with scleroderma take longer to perform daily living tasks, especially those that require hand strength and gripping objects, such as moving things between shelves, a new study found. ... Read more

December 2, 2019December 2, 2019

Health Canada Approves Ofev to Help Preserve Lung Health in People with SSc-ILD

News

Health Canada has approved Ofev (nintedanib) as a treatment to slow the decline of pulmonary function in people with scleroderma-associated interstitial lung disease (SSc-ILD). The approval makes Ofev, by Boehringer Ingelheim, the first treatment ... Read more

Pin It on Pinterest